Table 3.
Economic Impact of Knee Osteoarthritis Treatment with/without CS
| Treatment Duration (Days) | Year | Savings from Avoiding AE | Additional Cost of the CS | Net Savings from Avoiding AE with the CS | Probability of Savings with CS |
|---|---|---|---|---|---|
| 180 | 2020 | €13,540,448 | €6,249,466 | €-7,291,022 | 72.2% |
| 2021 | €13,774,179 | €6,374,456 | €-7,399,724 | ||
| 2022 | €13,630,133 | €6,501,945 | €-7,128,188 | ||
| Total | €40,944,800 | €19,125,867 | €-21,818,933 | ||
| 90 | 2020 | €12,907,221 | €3,124,733 | €-9,782,488 | 74.0% |
| 2021 | €13,148,524 | €3,187,228 | €-9,961,296 | ||
| 2022 | €13,008,602 | €3,250,927 | €-9,757,629 | ||
| Total | €39,064,347 | €9,562,934 | €-29,501,413 | ||
| 240 | 2020 | €12,492,110 | €8,332,622 | €-4,159,488 | 68.0% |
| 2021 | €12,735,315 | €8,499,274 | €-4,236,040 | ||
| 2022 | €12,957,509 | €8,669,260 | €-4,288,249 | ||
| Total | €38,184,934 | €25,501,156 | €-12,683,778 |
Abbreviation: CS, chondroitin sulfate with or without glucosamine.